GlassScriptPhysician profile
Claes U Svendsen
NPI 1801836572
$7,038.15
in general payments reported to CMS, 2019-2025
43 companies · $562 in 2025
The $562 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,131 · 2020: $520 · 2021: $1,210 · 2022: $1,604 · 2023: $1,089 · 2024: $922 · 2025: $562.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,573.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,572.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,036.21 | 2021-2025 | Vraylar, Ubrelvy |
| Novo Nordisk INC | $942.60 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $612.91 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $458.47 | 2019-2025 | |
| Glaxosmithkline, LLC. | $411.09 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Amgen INC. | $388.11 | 2019-2025 | Otezla, Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $280.82 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $267.26 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $265.71 | 2019-2024 | Xifaxan, Plenvu |
| Allergan, INC. | $234.94 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $230.73 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $179.70 | 2019-2024 | Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $150.45 | 2022 | |
| Xeris Pharmaceuticals, INC. | $150.03 | 2021-2025 | Gvoke Hypopen |
| Dexcom, INC. | $141.87 | 2021-2025 | Dexcom G6 Transmitter |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Claes Svendsen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.